INTERMEDIATE DOSE ARA-C AND AMSA FOR TREATMENT OF RELAPSED AND REFRACTORY ADULT AML

被引：0
|
作者：
JEHN, U [1 ]
KOLB, HJ [1 ]
WILMANNS, W [1 ]
机构：
[1] UNIV MUNICH, MED KLIN 3, D-8000 MUNICH 70, FED REP GER
来源：
BLUT | 1988年 / 57卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：190 / 190
页数：1
相关论文
共 50 条
  • [31] Selinexor, ARA-C and Idarubicin: An Effective and Tolerable Combination in Patients with Relapsed/Refractory AML: A Multicenter Phase II Study
    Fiedler, Walter
    Chromik, Joerg
    Kebenko, Maxim
    Thol, Felicitas
    Trummer, Arne
    Schuenemann, Chirstoph
    Brandts, Christian H.
    Koehler, Anne
    Schlipfenbacher, Vera
    Bokemeyer, Carsten
    Theile, Susann
    Kranich, Anne L.
    Heuser, Michael
    BLOOD, 2015, 126 (23)
  • [32] TREATMENT OF AML WITH CYTOSINE-ARABINOSIDE (ARA-C) AND ANTHRACYCLINE
    PREISLER, H
    RUSTUM, Y
    HENDERSON, E
    BJORNSSON, S
    HIGBY, D
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1978, 19 (MAR): : 389 - 389
  • [33] A novel effective and safe consolidation regimen for elderly patients with AML: Intermediate dose intermittent ARA-C (IDAC).
    Sperr, WR
    Piribauer, M
    Wimazal, F
    Fonatsch, C
    Thalhammer-Scherrer, R
    Schwarzinger, I
    Geissler, K
    Knoebel, P
    Jaeger, U
    Lechner, K
    Valent, P
    BLOOD, 2002, 100 (11) : 342A - 343A
  • [34] Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia
    Cortes, J
    Estey, E
    Beran, M
    O'Brien, S
    Giles, F
    Koller, C
    Keating, M
    Kantarjian, H
    LEUKEMIA & LYMPHOMA, 2000, 36 (5-6) : 479 - 484
  • [35] Low Dose Ara-C Versus Low Dose Ara-C and Tipifarnib: Result of the UK NCRI AML16 "Pick a Winner" Comparison
    Burnett, Alan K.
    Hills, Robert
    Milligan, Donald
    Kell, William J.
    Wheatley, Keith
    Virchis, Andres E.
    Russell, Nigel H.
    BLOOD, 2008, 112 (11) : 1017 - 1018
  • [36] TREATMENT OF MDS WITH LOW-DOSE ARA-C
    MILLER, K
    GEMATOLOGIYA I TRANSFUZIOLOGIYA, 1995, 40 (02): : 13 - 13
  • [37] Phase II trial of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide as salvage therapy for refractory or relapsed acute leukemia
    Sung, WJ
    Kim, DH
    Sohn, SK
    Kim, JG
    Baek, JH
    Jeon, SB
    Moon, JH
    Ahn, BM
    Lee, KB
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2005, 35 (10) : 612 - 616
  • [38] Autophagy induction of Acute Myeloid Leukemia (AML) cells after treatment with low dose-cytarabine (Ara-C) and enhanced cytocidal effect on AML cells by combined treatment with ara-c plus lenograstim
    Tang, Yongmin
    Li, Lixia
    Wang, Di
    Shen, Hongqiang
    Qian, Baiqin
    Luo, Chunfang
    Zhang, Haizhong
    BLOOD, 2007, 110 (11) : 114B - 114B
  • [39] HIGH-DOSE ARA-C AND ETOPOSIDE IN THE TREATMENT OF REFRACTORY OR RELAPSING ACUTE-LEUKEMIA
    FREUND, M
    LINK, H
    DIEDRICH, H
    WILKE, JJ
    SCHMOLL, HJ
    POLIWODA, H
    BLUT, 1987, 55 (04): : 215 - 215
  • [40] CONTINUOUS LOW-DOSE INFUSIONS OF ARA-C IN MANAGEMENT OF PATIENTS WITH AML
    POTTER, CG
    BUNCH, C
    PIPPARD, MJ
    ROWELL, AC
    BRITISH JOURNAL OF CANCER, 1978, 38 (01) : 181 - 181
12345